论文部分内容阅读
1975年发现雌孕激素口服避孕药制造者的血凝机制受到不良影响,因此要求政府医药顾问服务中心协助解决。本文作者对制造口服避孕药工人作了观察。研究对象分2组:A组在制造过程与药物密切接触者,包括1男2女,年龄均超过50岁,在设置防护措施后1年内每4～6周检查1次作连续观察。B组与药物接触较间接者,包括7男9女(其中2例女性由于不到45岁而除外),此组大多数只检查1次。对照组为有绝经期症状的妇女而采用内分泌替代治疗者,共28例。结果A组2例妇女均有间歇阴道出血及一些绝经症状;其中1例皮肤光滑性增加,另1例乳腺增大,体检无异常;该例男性有糖尿病及女性乳房;3例血压均正常,无血栓栓塞性疾患。B组7例妇女中4例有间歇性阴道出血,其中3例为绝经后,另1例
In 1975, it was found that the mechanism of hemagglutination of the manufacturers of estrogen and progestin oral contraceptive pills was adversely affected. Therefore, the government medical consultant service center was requested to help solve the problem. The author of this article observed the manufacture of oral contraceptives workers. Participants were divided into two groups: group A, who were in close contact with the drug during the manufacturing process, including 1 male and 2 female, both of whom were over 50 years of age. The patients were examined continuously every 4 to 6 weeks for 1 year after the protective measures were set. Patients in group B were more likely to be exposed to drugs than those who were indirect, including 7 males and 9 females (2 of whom were less than 45 years old), and most of the group was checked only once. The control group of women with menopausal symptoms and endocrine replacement therapy, a total of 28 cases. Results A group of 2 women had intermittent vaginal bleeding and some menopausal symptoms. Among them, one had smooth skin and the other had enlarged breast with no abnormal physical examination. The male had diabetes and female breasts, three had normal blood pressure, Thromboembolic disorders. 4 of the 7 women in group B had intermittent vaginal bleeding, 3 of whom were postmenopausal and the other 1